Benznidazole and Chagas disease: Can an old drug be the answer to an old problem?

Expert Opinion on Investigational Drugs

Volumn 17, Issue 10, 2008, Pages 1427-1433

  Mady, Charles ^a   Ianni, Barbara Maria ^a   de Souza Jr , José Leáo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Benznidazole; Chagas disease; Free radicals; Treatment

Indexed keywords

ANTIPARASITIC AGENT; BENZNIDAZOLE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NIFURTIMOX; PLACEBO; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANOREXIA; ARTHRALGIA; BLOOD CULTURE; CHAGAS DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ECG ABNORMALITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGASTRIC PAIN; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INJURY; HEMAGGLUTINATION; HEMATOLOGIC DISEASE; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LOW DRUG DOSE; LYMPHADENOPATHY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MENTAL DISEASE; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NEURITIS; PATHOGENESIS; POLYNEUROPATHY; PREGNANCY; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN ALLERGY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TRYPANOSOMA CRUZI; VOMITING; WEIGHT REDUCTION; XENODIAGNOSIS;

ADOLESCENT; ADULT; CHAGAS DISEASE; CHILD; HUMANS; MIDDLE AGED; NIFURTIMOX; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS;

EID: 52949090075     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.10.1427     Document Type: Review

References (42)

1. Akhavan D. Analysis of cost-effectiveness of the program of control of Chagas disease in Brazil. PAHO/WHO. Representation of Brazil. Brasilia 2000
2. Dias JCP. Globalization, inequity and Chagas disease. Rio de Janeiro. Cad Saude Publica 2007;1(23 Suppl):S13-22
3. Castro SL, Soeiro MN. The research of new drugs for the treatment of Chagas disease. Available from: http://www.fiocruz.br/chagas [Last accessed 2008 July 2]
4. Simões MV, Almeida Filho OC, et al. Heart failure in Chagas disease. Rev Soc Cardiol Estado de Sao Paulo 2000;10:50-64
5. Mady C, Cardoso RHA, Barreto ACP, et al. Survival and predictors of survival in congestive heart failure due to Chagas' cardiomyopathy. Circulation 1994;30:98-102
6. Freitas HFG, Chizzola PR, Paes AT, et al. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Int J Cardiol 2005;102:239-47
7. Higuchi ML, Benvenuti LA, Reis MM, et al. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res 2003;60:96-107
8. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109-23
9. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006;19:583-7
10. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States. JAMA 2007;298:2171-81
11. Apt W, Arribada A, Zulantay I, et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasit 2005;99:733-41
12. Moreira A, de Souza H, Amato Neto V, et al. Evaluation of the therapeutic activity of itraconazole in chronic infections, experimental and human, by Trypanosoma cruzi. Rev Inst Med Trop S Paulo 1992;34:177-80
13. Nozaki T, Engel JC, Dvorak JA. Cellular and molecular biological analyses of nifurtimox resistance in Trypanosoma cruzi. Am J Trop Med Hyg 1996;55:111-7
14. Murta SM, Gazzinelli RT, Brener Z, Romanha AJ. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol 1998;93:203-14
15. Urbina JA, Concepcion JL, Caldera A, et al. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 2004;48:2379-87
16. Zaidenberg A, Luong T, Lirussi D, et al. Treatment of experimental chronic Chagas disease with trifluralin. Basic Clin Pharmacol Toxicol 2006;98:351-6
17. Ferraz ML, Gazzinelli RT, Alves RO, et al. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 2007;51:1359-64
18. Docampo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 1990;73:1-27
19. Paulos C, Paredes J, Vasquez I, et al. Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1989;27:454-7
20. Urbina JA. Chemotherapy of Chagas disease. Curr Pharm Des 2002;8:287-95
21. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease. Hum Exp Toxicol 2006;25:471-9
22. Etiological treatment of Chagas disease. 2nd edition. Technical Management of Chagas Disease. Coordination of Diseases Transmitted by Vectors. Brasilia: National Foundation of Health; 1996. p. 32
23. Brasilian consensus in Chagas disease. Rev Soc Bras Med Trop 2005;38(Suppl III):3-29
24. Sosa Estani S, Segura EL. Treatment of Trypanosoma cruzi infection in the undetermined phase: experience and current guidelines of treatment in Argentina. Mem Inst Oswaldo Cruz 1999;94(Suppl I):363-5
25. Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz 2007;102(Suppl I):95-7
26. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop S Paulo 2002;44:29-37
27. Cançado JR. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz 1999;94(Suppl I):331-5
28. Gontijo ED, Galvao LMC, Eloi-Santos S. Chagas disease: criteria of cure and prognosis. Mem Inst Oswaldo Cruz 1999;94(Suppl I):357-62
29. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Intern Med 2006;144:724-34
30. Britto C, Cardoso MA, Vanni CM, et al. Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology 1995;110:241-7
31. Gomes ML, Galvao LM, Macedo AM, et al. Chagas' disease diagnosis: comparative analysis of parasitologic, molecular and serologic methods. Am J Trop Med Hyg 1999;60:205-10
32. Britto C. Molecular diagnosis of Chagas disease. Available from: http://www.fiocruz.br/chagas [Last accessed 2008 August 8]
33. Andrade ALSS, Zicker F, Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348:1407-13
34. Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998;59:526-9
35. Luquetti AO. Etiological treatment for chagas disease: The National Health Foundation of Brazil. Parasitol Today 1997;13:127-8
36. Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease. Cochrane Database Sys Rev 2008;CD004102
37. Ianni BM, Arteaga E, Mady C, et al. Treatment with benznidazole in patients in indeterminate form of Chagas disease: results after a long follow-up. Arq Bras Cardiol 1993;61(Suppl II):130
38. Coura JR, de Abreu LL, Willcox HP, et al. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. Preliminary evaluation. Rev Soc Bras Med Trop 1997;30:240-5
39. Ianni BM, Arteaga E, Frimm CC, et al. Chagas' heart disease: evolutive evaluation of electrocardiographic and echocardiographic parameters in patients with the indeterminate form. Arq Bras Cardiol 2001;77:59-62
40. Marin-Neto JA, Rassi A Jr, Morillo CA, et al. BENEFIT Investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the Benznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008;156:37-43
41. Genzyme Corp. website. Available from: http://www.genzyme.com [Last accessed 2008 August 8]
42. Ianni BM, Mady C. Therapeutics for the chronic form of Chagas' disease. Is the etiological treatment effective? Arq Bras Cardiol 1998;70:59-60